Please use this identifier to cite or link to this item: https://doi.org/10.1186/s13148-021-01153-y
Title: Betamethasone administration during pregnancy is associated with placental epigenetic changes with implications for inflammation
Authors: Czamara, Darina
Dieckmann, Linda
Röh, Simone
Kraemer, Sarah
Rancourt, Rebecca C.
Sammallahti, Sara
Kajantie, Eero
Laivuori, Hannele
Eriksson, Johan G. 
Räikkönen, Katri
Henrich, Wolfgang
Plagemann, Andreas
Binder, Elisabeth B.
Braun, Thorsten
Entringer, Sonja
Keywords: Betamethasone
DNA methylation
FKBP5
Gene expression
Placenta
Targeted bisulfite sequencing
Issue Date: 26-Aug-2021
Publisher: BioMed Central Ltd
Citation: Czamara, Darina, Dieckmann, Linda, Röh, Simone, Kraemer, Sarah, Rancourt, Rebecca C., Sammallahti, Sara, Kajantie, Eero, Laivuori, Hannele, Eriksson, Johan G., Räikkönen, Katri, Henrich, Wolfgang, Plagemann, Andreas, Binder, Elisabeth B., Braun, Thorsten, Entringer, Sonja (2021-08-26). Betamethasone administration during pregnancy is associated with placental epigenetic changes with implications for inflammation. Clinical Epigenetics 13 (1) : 165. ScholarBank@NUS Repository. https://doi.org/10.1186/s13148-021-01153-y
Rights: Attribution 4.0 International
Abstract: Background: Glucocorticoids (GCs) play a pivotal role in fetal programming. Antenatal treatment with synthetic GCs (sGCs) in individuals in danger of preterm labor is common practice. Adverse short- and long-term effects of antenatal sGCs have been reported, but their effects on placental epigenetic characteristics have never been systematically studied in humans. Results: We tested the association between exposure to the sGC betamethasone (BET) and placental DNA methylation (DNAm) in 52 exposed cases and 84 gestational-age-matched controls. We fine-mapped associated loci using targeted bisulfite sequencing. The association of placental DNAm with gene expression and co-expression analysis on implicated genes was performed in an independent cohort including 494 placentas. Exposure to BET was significantly associated with lower placenta DNAm at an enhancer of FKBP5. FKBP5 (FK506-binding protein 51) is a co-chaperone that modulates glucocorticoid receptor activity. Lower DNAm at this enhancer site was associated with higher expression of FKBP5 and a co-expressed gene module. This module is enriched for genes associated with preeclampsia and involved in inflammation and immune response. Conclusions: Our findings suggest that BET exposure during pregnancy associates with few but lasting changes in placental DNAm and may promote a gene expression profile associated with placental dysfunction and increased inflammation. This may represent a pathway mediating GC-associated negative long-term consequences and health outcomes in offspring. © 2021, The Author(s).
Source Title: Clinical Epigenetics
URI: https://scholarbank.nus.edu.sg/handle/10635/231918
ISSN: 1868-7075
DOI: 10.1186/s13148-021-01153-y
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s13148-021-01153-y.pdf1.6 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons